Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety

BACKGROUND/AIMS: The treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis C virus (HCV) infection. We investigated the real-world efficacy, changes in liver stiffness and noninvasive fibrosis markers, and the safety...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Gut Liver
Hlavní autoři: Lee, Hye Won, Oh, Se Rim, Kim, Dong Yun, Jeong, Yechan, Kim, Seungtaek, Kim, Beom Kyung, Kim, Seung Up, Kim, Do Young, Ahn, Sang Hoon, Han, Kwang-Hyub, Park, Jun Yong
Médium: Artigo
Jazyk:Inglês
Vydáno: Editorial Office of Gut and Liver 2018
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5945264/
https://ncbi.nlm.nih.gov/pubmed/29409309
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5009/gnl17298
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky